Sean Brynjelsen

Sean Brynjelsen (chief executive) discloses dealings in Eton Pharmaceuticals, Inc. to SEC (Form 4). Between 3 June 2021 and 20 August 2026, the trades on record add up to 14 filings.

On the open market, the record shows 3 purchases worth €83k and 7 sales worth €9.4M. Sales outweigh purchases by €9.4M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 2 share grants and 2 option exercises. Since January 2026: no purchases and 6 sales on the market.

In size, the median ticket on the buying side is €25k. On 1 out of 3 purchases, another insider of the same company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

On 20 August 2026 came the latest disclosure, an open-market sale for €486k in Eton Pharmaceuticals, Inc. The latest purchase dates back some time: it was published 1,486 days ago, on 23 September 2022. The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.